RxDoctor Payments Data

Jodi Newman

Family · Litchfield Park, AZNPI 1518329218

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 67.4% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $142, 8.1 times the $17 reported in 2022. That places this record below the midpoint for family clinicians in AZ, where the typical reported total is $331.

$222in general payments, 2019–2025

Across 5 payments — averaging $44.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$150
  • Urgo Medical North America, LLC$38
  • KCI USA, Inc.$17
  • Solventum Corporation$17

What the payments were for

  • Food & beverage$222100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$222 in reported general payments places this provider in the 40th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona →

Medicare billing

Part B allowed, 2024
$4,043,460
Medicare patients
64
Services billed
2,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate16$85,634
EliquisApixaban87$58,241
OzempicSemaglutide20$22,275
TrulicityDulaglutide19$19,686
JardianceEmpagliflozin28$15,265
JanuviaSitagliptin Phosphate25$14,126
LinzessLinaclotide21$12,584
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,280
XareltoRivaroxaban14$9,462
Gabapentin252$8,476
SymbicortBudesonide/Formoterol Fumarate16$4,874
Atorvastatin Calcium254$4,530
Quetiapine Fumarate175$3,994
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$3,693
Levetiracetam58$3,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$150$12,58421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 4,119 family providers in Arizona.

Other family in Litchfield Park

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →